title: Plasma visfatin, a possible prognostic marker in aneurysmal subarachnoid hemorrhage.
abstract: Visfatin is linked to inflammation and associated with clinical outcomes of intracerebral hemorrhage. This study was designed to investigate whether visfatin might serve as a marker of severity and prognosis in aneurysmal subarachnoid hemorrhage. In this study, plasma visfatin levels of 172 consecutive patients and 172 sex and age-matched healthy subjects were determined using enzyme-linked immunosorbent assay. The recorded clinical outcomes included in-hospital mortality and 6-month mortality and unfavorable outcome (Glasgow Outcome Scale score of 1-3). Plasma visfatin level was substantially higher in patients than in healthy controls (92.1 ± 20.5 ng/mL vs. 12.4 ± 3.2 ng/mL; P<0.001), was significantly associated with the World Federation of Neurological Surgeons (WFNS) score (r=0.569, P<0.001) and Fisher score (r=0.657, P<0.001), was an independent predictor of in-hospital mortality [odds ratio (OR), 1.378; 95% confidence interval (CI), 1.036-1.866; P=0.002] and 6-month mortality (OR, 1.261; 95% CI, 1.018-1.745; P=0.004) and unfavorable outcome (OR, 1.207; 95% CI, 1.012-1.682; P=0.008) in multivariate logistic regression analysis and had high predictive value for in-hospital mortality [area under curve (AUC), 0.849; 95% CI, 0.787-0.899; P<0.001] and 6-month mortality (AUC, 0.868; 95% CI, 0.808-0.915; P<0.001) and unfavorable outcome (AUC, 0.859; 95% CI, 0.797-0.907; P<0.001) using receiver operating characteristic curves. AUCs of visfatin were similar to those of WFNS score and Fisher score (all P>0.05), but visfatin did not improve the predictive values of WFNS score and Fisher score (all P>0.05). Thus, visfatin may be associated with clinical severity of aneurysmal subarachnoid hemorrhage and also have prognostic value for clinical outcomes.
authors.affiliation: Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou 310000, PR China.
authors.forename: Jun-Xing
authors.initials: JX
authors.lastname: Wang
authors.forename: Yong
authors.initials: Y
authors.lastname: Hou
authors.forename: Shan-Ping
authors.initials: SP
authors.lastname: Ruan
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Hu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D023261:Glasgow Outcome Scale; D006801:Humans; D002532:Intracranial Aneurysm / Q000097:blood* / Q000150:complications / Q000175:diagnosis / Q000401:mortality; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D011379:Prognosis; D012372:ROC Curve; D013345:Subarachnoid Hemorrhage / Q000097:blood* / Q000175:diagnosis / Q000209:etiology / Q000401:mortality; D016019:Survival Analysis
chemical_list: D015415:Biomarkers; D016207:Cytokines; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human
keywords: Aneurysmal subarachnoid hemorrhage; Biomarker; Prognosis; Visfatin